Aurora to Present at Upcoming Investor Conferences

PITTSBURGH--(BUSINESS WIRE)-- Aurora Innovation, Inc. (NASDAQ: AUR) today announced its executives will present at two upcoming investor conferences:

• Aurora’s Chief Financial Officer, Richard Tame, will participate in a fireside chat at the KeyBanc Capital Markets 2023 Emerging Technology Summit on March 7, 2023 at 4:00 pm Eastern time.
• Aurora’s Chief Executive Officer, Chris Urmson, will participate in a fireside chat at the J.P. Morgan 2023 Industrials Conference on March 16, 2023 at 11:20 am Eastern time.

The presentations will be webcast on Aurora’s investor relations website at ir.aurora.tech. A replay of the webcasts will be available for 30 days following the live presentation.

About Aurora

Aurora (Nasdaq: AUR) is delivering the benefits of self-driving technology safely, quickly, and broadly to make transportation safer, increasingly accessible, and more reliable and efficient than ever before. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling semi-trucks to ride-hailing passenger vehicles, and underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. Aurora is working with industry leaders across the transportation ecosystem, including Toyota, FedEx, Volvo Trucks, PACCAR, Uber, Uber Freight, U.S. Xpress, Werner, Covenant, Schneider, and Ryder. For Aurora’s latest news, visit aurora.tech and @aurora_inno on Twitter.

Aurora Overview
Aurora Press Kit

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005461/en/

Investor Relations:
Stacy Feit
[email protected]
(323) 610-0847

Media:
Khobi Brooklyn
[email protected]
(415) 699-3657

Source: Aurora Innovation, Inc.

You May Also Be Interested In

• Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
• The Exhibition Hall of Achievements of China's Language Resources Protection Project Officially Opens
• RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer